Advantages of aspirin in the prevention of cardiovascular disease
Keywords:
Cardiovascular Disease, Aspirin, preventifAbstract
Headache medicine treatment is perceived as a specialist in the adjunctive anticipation of cardiovascular occasions, and ongoing rules likewise characterize the job of aspirin in fundamental evasion. This review presents the fundamentals of anti-inflammatory medicine use as far as stream rules, makes sense of the elements that might influence the adequacy of ibuprofen treatment in the anticipation of cardiovascular illness, and momentarily surveys models for the reason increment. Proof backings the utilization of anti-inflammatory medicine in the deliberate and fundamental counteraction of cardiovascular occasions in specific populaces, yet commonsense models might need. Aspirin ought to be painstakingly thought to be as an essential and judicious cardiovascular infection anticipation technique in all grown-up patients in danger and requires further activity, like patient instruction, to guarantee appropriate use. Headache medicine is the premise of laid out antithrombotic treatment for patients with atherosclerosis, yet significant guideline is conflicting with its utilization in basic prophylaxis.
Downloads
References
Soni A. Aspirin use among the adult U.S. non institutionalized population, with and without indicators of heart disease, 2005. Statistical Brief #129 Agency for Healthcare Research and Quality, Medical Expenditure Panel Survey; Accessed February 6, 2013.
Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation 2011;123:768–778.
Miner J, Hoffhines A. The discovery of aspirin’s antithrombotic effects Tex Heart Inst J 2007;34:179–186.
Dippel DW, Van Kooten F, Leebeek FW, van Vilet HH, Mehicevic A, Li SS, Koudstaal PJ. What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? Cerebrovasc Dis 2004;17:296–302.
Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: a meta-analysis on 376,162 patients. Am J Med 2012;125:882–887.e1.
Vanwormer JJ, Greenlee RT, McBride PE, Peppard PE, Malecki KC, Che J, Nieto FJ. Aspirin for primary prevention of CVD: are the right people using it? J Fam Pract 2012;61:525533.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349–360
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 2002; 324:71–86.
American Heart Association Website Aspirin and Heart Disease Accessed March 14, 2013.
Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, Gupta A, Kraw ME, Lindsay TF, Love MP, Pannu N, Rabasa-Lhoret R, Shuaib A, Teal P, Théroux P, Turpie AG, Welsh RC, Tanguay JF. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol 2011; 27:208221
Centers for Disease Control and Prevention. National Center for Health Statistics Deaths and Mortality May 3, 2017.
Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Lévy G, Pelletier E, Juneau M, Stasiak J, deGuise P, et al.. Aspirin, heparin, or both to treat acute unstable angina 1988; 319:1105–1111 doi: 10.1056/NEJM198810273191701
Baigent C, Sudlow C, Collins R and Peto R. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.BMJ. 2002; 324:71–86 doi: 10.1136/bmj.324.7329.71.
Patron C, Garcia Rodriguez LA, Lanolin R and Beignet C. Low-dose aspirin for the prevention of atherothrombosis N Eng J Med. 2005; 353:2373–2383. doi: 10.1056/NEJMra052717.
Bobbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med. 2016; 164:836–845. doi: 10.7326/M16-0577.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
